Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer
Status:
Not yet recruiting
Trial end date:
2029-01-01
Target enrollment:
Participant gender:
Summary
Randomized, open label, phase II multicenter study to assess the efficacy niraparib versus
niraparib +bevacizumab maintenance in patients with newly diagnosed stage IIIA/B/C high-grade
epithelial ovarian cancer with no residual disease after frontline surgery and treatment by
adjuvant platinum-basedchemotherapy +/-bevacizumab.